Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 441-447

  Køllgaard, Tania ^a   Klausen, Tobias Wirenfeldt ^a   Idorn, Manja ^a   Holmgaard, Rikke Bæk ^a   Straten, Per Thor ^a   Andersen, Mads Hald ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Genotype; IDO2; SNP; Spontanous immune responses; T cell antigen

Indexed keywords

HLA A2 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE;

ADAPTIVE IMMUNITY; ALLELE; ARTICLE; BREAST CANCER; CATALYSIS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; T LYMPHOCYTE;

EID: 84886944226     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19654     Document Type: Article

References (16)

1. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-3900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35
2. Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle 2009; 8:1818-1819; PMID:19471123; http://dx.doi.org/10.4161/cc.8.12.8887
3. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007; 7:31-40; PMID:17305476; http://dx.doi.org/10.2174/156800907780006896
4. Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008; 27:2851-2857; PMID:18026137; http://dx.doi.org/10.1038/sj.onc.1210939
5. Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, et al. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008; 51:4968-4977; PMID:18665584; http://dx.doi.org/10.1021/jm800512z
6. Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem 2008; 51:1706-1718; PMID:18318466; http://dx.doi.org/10.1021/jm7014155
7. Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, et al. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther 2010; 9:1864-1871; PMID:20530717; http://dx.doi.org/10.1158/1535-7163.MCT-10-0185
8. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801; PMID:17234791; http://dx.doi.org/10.1158/0008-5472.CAN-06-2925
9. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7082-7087; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872
10. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009; 208:781-787, discussion 787-9; PMID:19476837; http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.018
11. Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, et al. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 2011; 71:2038-2044; PMID:21406395; http://dx.doi.org/10.1158/0008-5472.CAN-10-3403
12. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol 2010; 176:2082-2087; PMID:20228228; http://dx.doi.org/10.2353/ajpath.2010.091173
13. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-319; PMID: 15711557; http://dx.doi.org/10.1038/nm1196
14. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009; 208:781-787, discussion 787-9; PMID:19476837; http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.018
15. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61:869-872; PMID: 11221872
16. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210:149-166; PMID:9520298; http://dx.doi.org/10.1016/S0022-1759(97)00182-8